<span item_type="fundamental" item_id="e04adfec9dc26f8642218a57a4344e77" counter_id="ST/US/GOVXW" env="prod"></span><span item_type="announcement" item_id="511404699968932993" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 1.637 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.45.</p><p></p><h3>Net Loss</h3><p>Net loss for the three months ended March 31, 2025, was $5.4 million, compared to $5.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p><h3>Revenue</h3><p>For the three months ended March 31, 2025, GeoVax reported $1.6 million in government contract revenues associated with the BARDA/RRPV Project NextGen award, whereas no revenues were reported during the comparable 2024 period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p><h3>Research and Development Expenses</h3><p>Research and development expenses were $5.4 million for the three months ended March 31, 2025, compared to $4.4 million for the same period in 2024, primarily due to costs associated with the BARDA/RRPV Project NextGen award and the Gedeptin and GEO-MVA programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p><h3>General and Administrative Expenses</h3><p>General and administrative expenses were $1.7 million for the three months ended March 31, 2025, compared to $1.5 million for the same period in 2024, with the increase primarily due to higher investor relations consulting costs and stock-based compensation expense.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p><h3>Cash Position</h3><p>GeoVax reported cash balances of $7.4 million at March 31, 2025, compared to $5.5 million at December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p><h3>Outlook / Guidance</h3><p>GeoVax anticipates key data readouts for its GEO-CM04S1 COVID-19 vaccine program in the first half of 2025, with clinical trials for GEO-MVA expected to initiate in the second half of 2025. The company is advancing its Gedeptin technology into Phase 2 trials for head and neck cancer, reflecting a strategic focus on innovative immunotherapies and vaccines.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm"></span></p>

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 1.637 M